SCHEMBL4595052

SCHEMBL4595052

O=Cc1ccc(OCCOCCO)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.53
ALDH1A1 P00352 8/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
HPGD P15428 2/20 0.51
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49
SLCO1B3 Q9NPD5 1/20 0.49
SLCO1B1 Q9Y6L6 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
RECQL P46063 1/20 0.42
CYP2A6 P11509 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3861084 1.00 APP (0.53) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL2229143 1.00 APP (0.53) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL8371513 0.91 ALDH1A1 (0.59) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL19389642 0.90 ALDH1A1 (0.53) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL145373 0.89 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL22190238 0.88 APP (0.68) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL11685734 0.86 ALDH1A1 (0.50) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL22190246 0.86 APP (0.59) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL22190239 0.86 APP (0.59) APPALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL21959668 0.85 APP (0.58) APPALDH1A1SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112500325-A Alpha, omega-type chain transfer agent for reversible addition-fragmentation chain transfer RAFT polymerization, and preparation method and application thereof 北京吉乃尔科技有限公司 2021-03-16 CN claimed
US-11814402-B2 Binuclear palladacycles and their use in the treatment of cancer STELLENBOSCH UNIVERSITY (ZA) 2023-11-14 US disclosed
US-11814402-B2 Binuclear palladacycles and their use in the treatment of cancer STELLENBOSCH UNIVERSITY (ZA) 2023-11-14 US disclosed
US-11814402-B2 Binuclear palladacycles and their use in the treatment of cancer STELLENBOSCH UNIVERSITY (ZA) 2023-11-14 US disclosed
CN-116947641-A Polymerizable photoinitiator containing diphenyl ketone structure and preparation method thereof 宁波力合博汇光敏材料有限公司 2023-10-27 CN disclosed
EP-3752513-B1 BINUCLEAR PALLADACYCLES AND THEIR USE IN THE TREATMENT OF CANCER UNIV STELLENBOSCH (ZA) 2021-10-20 EP disclosed
CN-112500325-A Alpha, omega-type chain transfer agent for reversible addition-fragmentation chain transfer RAFT polymerization, and preparation method and application thereof 北京吉乃尔科技有限公司 2021-03-16 CN disclosed
CN-112500325-A Alpha, omega-type chain transfer agent for reversible addition-fragmentation chain transfer RAFT polymerization, and preparation method and application thereof 北京吉乃尔科技有限公司 2021-03-16 CN disclosed
CN-108440251-B Method for photo/nickel concerted catalysis of monoarylation diol 陕西师范大学 2021-01-01 CN disclosed
EP-3752513-A1 BINUCLEAR PALLADACYCLES AND THEIR USE IN THE TREATMENT OF CANCER Stellenbosch University (ZA) 2020-12-23 EP disclosed
US-20040204510-A1 High internal phase emulsion foams containing polyelectrolytes 3M INNOVATIVE PROPERTIES COMPANY 2004-10-14 US disclosed
US-6750261-B1 High internal phase emulsion foams containing polyelectrolytes 3M INNOVATIVE PROPERTIES COMPANY 2004-06-15 US disclosed
EP-0885408-B1 A SCREEN PRINTING STENCIL SERICOL LTD (GB) 2001-10-17 EP disclosed
US-5994033-A GRAFT POLYMER SERICOL LIMITED (GB) 1999-11-30 US disclosed
EP-0885408-A1 A SCREEN PRINTING STENCIL SERICOL LIMITED (GB) 1998-12-23 EP disclosed
US-5674561-A APPLYING TO BACKING A POLYMER BLEND HAVING COEXISTING CONTINUOUS HYDROPHILIC AND HYDROPHOBIC SOLID PHASES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-10-07 US disclosed
WO-1997033202-A1 A SCREEN PRINTING STENCIL SERICOL LIMITED (GB) 1997-09-12 WO disclosed
EP-0594702-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS. UPJOHN CO (US) 1994-05-04 EP disclosed
US-5091274-A Modified polysiloxanes NATIONAL SCIENCE COUNCIL (TW) 1992-02-25 US disclosed
US-4053415-A UNSATURATED POLYESTER ETHER HAVING A PHOTOCROSSLINKABLE MOIETY FUJI PHOTO FILM CO., LTD. (JA) 1977-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814402-B2 Binuclear palladacycles and their use in the treatment of cancer BCL3, CCNO, CCNE2 APP 4861/4885ALDH1A1 985/4885SMN1; SMN2 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.